No Data
No Data
Here's Why Royalty Pharma (NASDAQ:RPRX) Has A Meaningful Debt Burden
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion.
Cytokinetics Slips 18% After It Announces Funding Collaboration With Royalty Pharma
Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline
Cytokinetics (CYTK) disclosed a collaboration late Wednesday under which Royalty Pharma (RPRX) will provide capital totaling up to $575 million to support the commercialization of aficamten and advanc
Cytokinetics Falls 10% on Royalty Pharma Transaction, Stock Offer
By Josh Beckerman Cytokinetics shares were down 10%, to $53.25, after hours as the biopharmaceutical company announced an expanded funding collaboration with Royalty Pharma totaling up to $575 millio
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company's expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed specialty cardiology business.